Zhang Yingjie, Inks Elizabeth S, Zhu Mengyuan, Chou C James, Fang Hao, Li Minyong, Shen Yuemao, Yi Fan, Xu Wenfang
Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, Ji'nan, Shandong, 250012, P. R. China.
RSC Adv. 2013 Nov 21;3(43). doi: 10.1039/C3RA43249A.
Histone deacetylase inhibitors (HDACi) are still the focus of epigenetic modulator development due to their effective intervention in many pathological processes. In our previous research, a potent HDACi was designed, synthesized and validated as a promising antitumor candidate named ZYJ-34c. Enlarged scale synthesis of ZYJ-34c for further detailed research was hindered by the occurrence of a by-product, which was identified as an isomer of ZYJ-34c by HRMS and H NMR. Subsequent synthesis route modification and optimization revealed that these two isomers were a pair of epimers and their absolute configurations could be directly determined by our optimized synthesis routes, through which each optically pure epimer could be stereoselectively synthesized, respectively. Based on these results, we concluded that our previously reported absolute configuration of ZYJ-34c was incorrect. It is worth noting that the epimer of ZYJ-34c exhibited more potent HDACs inhibition and both in vitro and in vivo antitumor activities, and moreover, their different HDACs inhibitory activities could be rationalized by computational simulations of their binding modes in HDAC2.
组蛋白去乙酰化酶抑制剂(HDACi)因其对许多病理过程的有效干预,仍然是表观遗传调节剂开发的焦点。在我们之前的研究中,设计、合成并验证了一种有效的HDACi,它是一种名为ZYJ-34c的有前景的抗肿瘤候选物。由于一种副产物的出现,阻碍了ZYJ-34c的扩大规模合成以进行进一步的详细研究,通过高分辨质谱(HRMS)和氢核磁共振(H NMR)鉴定该副产物为ZYJ-34c的一种异构体。随后的合成路线修改和优化表明,这两种异构体是一对差向异构体,并且它们的绝对构型可以通过我们优化的合成路线直接确定,通过该路线可以分别立体选择性地合成每种光学纯的差向异构体。基于这些结果,我们得出结论,我们之前报道的ZYJ-34c的绝对构型是错误的。值得注意的是,ZYJ-34c的差向异构体表现出更强的组蛋白去乙酰化酶(HDACs)抑制作用以及体外和体内抗肿瘤活性,此外,它们不同的HDACs抑制活性可以通过其在HDAC2中的结合模式的计算模拟来解释。